“Along for the Ride”: A Qualitative Study Exploring Patient and Caregiver Perceptions of Decision Making in Cancer Care

Abstract

Background. Shared decision making is a cornerstone of an informed consent process for cancer treatment, yet there are often many physician and patient-related barriers to participation in the process. Decisions in cancer care are often perceived as relating to a discrete, treatment decision event, yet there is evidence that decisions are longitudinal in nature and reflect a multifactorial experience. Objective. To explore patient and caregiver perceptions of the choices and decision-making opportunities within cancer care. Design. Qualitative in-depth interviews with 37 cancer patients and 7 caregivers carried out as part of an evaluation of a cancer center’s effort to improve patient experience. Results. Participants described decision making related to four distinct phases in complex cancer care, with physicians leading, and often limiting, decisions related to disease assessment and treatment options and access, and patients leading decisions related to physician selection. Though physicians led many decisions, patients had a moderating influence on treatment, such that if patients did not like options presented, they would reconsider their options and sometimes switch physicians. Patients had various strategies for dealing with uncertainty when faced with decisions, such as seeking additional information to make an informed choice or making a conscious choice to defer decision making to the physician. Limitations. Patients were sampled from one academic cancer center that serves a predominantly Caucasian, Asian, and Hispanic/Latino population and received complex treatment. Conclusion. Because of the complexity of cancer treatment, many patients felt as though they were a “passenger” in decision making about care and did not lead many of the decisions, though many patients trusted their doctors to make the best decisions and were comforted by their expertise.

Two variants of ‘constrained participation’ in the care of vulnerable adults: A proof-of-concept study

“…However, studies show that patient preferences for participation differ between cultures, 13 individuals 14 and through each individual’s phases of illness. 15 Moreover, a mismatch between patient preferences for participation and the actual participation is linked to negative patient experiences, such as frustrations, 16 burden, 17 and dissatisfaction with care. 13 This is at odds with other conceptual studies that, as already outlined, addressed the positive impact of patient participation.…”

“…Holdsworth et al 15 provide an example of such excesses of ‘forced-to participation’ in their study involving cancer patients’ perception of decision-making within which they were forced to take decisions about issues that they feel unqualified to deal with. The results showed that shared decision-making was uncomfortable for those patients, who preferred that a physician led the decision and who had difficulties in assessing the information presented to them.…”

Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation

“…After initial discussion in the physician's office, the patient is given the IC for consideration of the risks, benefits, and required pretreatment testing, which can be burdensome and a deterrent to enrollment. 51,52 Telemedicine would allow this initial step to be conducted remotely. Additionally, opportunities to begin prescreening remotely by reviewing locally completed blood work, vital signs, and electrocardiograms would reduce delays and unnecessary travel especially for patients in remote areas.…”

Validation and clinical discovery demonstration of a real-world data extraction platform

“…Collectively, the processed data could be used for retrospective, observational research including regulated studies on novel therapies. RWD from this platform (hereinafter “Invitae’s Ciitizen platform”) has already been used as natural history data to support a successful Investigational New Drug application for a novel treatment for pediatric patients with a severe form of epileptic encephalopathy [8].…”